Business Description
Lipocine Inc
NAICS : 325412
SIC : 2834
ISIN : US53630X1046
Description
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.89 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -8.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 21 | |||||
| 3-Year EPS without NRI Growth Rate | 18.5 | |||||
| 3-Year FCF Growth Rate | 21.6 | |||||
| 3-Year Book Growth Rate | 1 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 12-1 Month Momentum % | -8.66 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.69 | |||||
| Quick Ratio | 8.69 | |||||
| Cash Ratio | 8.37 | |||||
| Days Payable | 59.7 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 289.2 | |||||
| Operating Margin % | 628.94 | |||||
| Net Margin % | 573.55 | |||||
| FCF Margin % | 411.96 | |||||
| ROE % | -58.82 | |||||
| ROA % | -54.58 | |||||
| ROIC % | -853.18 | |||||
| ROC (Joel Greenblatt) % | -13251.22 | |||||
| ROCE % | -58.61 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.19 | |||||
| Price-to-Tangible-Book | 1.19 | |||||
| EV-to-EBIT | 0.91 | |||||
| EV-to-EBITDA | 0.91 | |||||
| EV-to-Revenue | 5.2 | |||||
| EV-to-FCF | 1.36 | |||||
| Price-to-Net-Current-Asset-Value | 1.2 | |||||
| Price-to-Net-Cash | 1.25 | |||||
| Earnings Yield (Greenblatt) % | 110.31 | |||||
| FCF Yield % | -46.38 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lipocine Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | -2.676 | ||
| EPS (TTM) (€) | -2.838 | ||
| Beta | 0.9 | ||
| Volatility % | 14.18 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.000007 | ||
| 20-Day SMA (€) | 3.944 | ||
| 12-1 Month Momentum % | -8.66 | ||
| 52-Week Range (€) | 3.468 - 4.216 | ||
| Shares Outstanding (Mil) | 5.35 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lipocine Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lipocine Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lipocine Inc Frequently Asked Questions
What is Lipocine Inc(STU:2VT0)'s stock price today?
The current price of STU:2VT0 is €3.94. The 52 week high of STU:2VT0 is €4.22 and 52 week low is €3.47.
When is next earnings date of Lipocine Inc(STU:2VT0)?
The next earnings date of Lipocine Inc(STU:2VT0) is 2024-05-10 Est..
Does Lipocine Inc(STU:2VT0) pay dividends? If so, how much?
Lipocine Inc(STU:2VT0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers